©All rights reserved Aquapass 2025

Fluid Overload Management
Powered by Your Skin
Fluid Overload
Management Powered
by Your Skin

Non-invasive, Kidney Independent Solution

Aquapass technology enables excess fluid removal through the skin,

independent of kidney function – a first-of-its-kind approach

with two FDA Breakthrough Device Designations

Read more

A Growing Crisis in Fluid Overload

Over 17 million patients suffer from fluid overload due to heart or kidney failure, leading
to more than 3 million annual admissions, high readmission rates, and worsening outcomes
11.5M
Chronic Kidney
Disease Patients
6.2M
Heart Failure
Patients
850K
End-Stage Kidney
Disease Patients
Current therapies for fluid overload target the intravascular space, are ineffective
and carry a significant risk of complications.

Transforming the Skin into a Natural
Fluid Removal System

A patented technology that activates the eccrine (sweat) glands to remove excess fluid independent of kidney function. The system draws fluid directly from where it accumulates. The extravascular space.

Effective

High Volume Fluid Removal, >250 ml/hr

Controlled Decongestion

Easy to Use

Suited for Various Care Settings

Comfortable and Intuitive Design

Safe

Noninvasive and Kidney Independent

Stable Hemodynamics

Unlocking the Skin’s Potential

Like the kidneys, sweat glands clear fluid, electrolytes, and waste.
Kidney Nephron
Filter Water and
Electrolytes
Na+, Cl-, K+, Mg2+,
Ca2+
Urea and Uric Acid
↑Na+ Excretion at High Filtration Rate
Eccrine Gland
Excrete Water and
Electrolytes
Na+, Cl-, K+, Mg2+,
Ca2+
Urea, Uric Acid
and Heavy Metals
↑Na+ Excretion at High Sweat Rate
Kidney Nephron
Eccrine Gland
Ultrafiltration & Clearence
Selective electrolyte reabsorption
Excretion of metabolic byproducts
High sodium excretion

One Solution Spanning Multiple Care Settings

Seamless integration across all treatment environments

Emergency Admission

  • Easy to deploy
  • Rapid patient response

Inpatient Care

  • High fluid volume removal
  • Patient’s comfort

Outpatient Care

  • Reduction in diuretic dosages
  • Simple Transition Of Care (TOC)

Promising Safety and Effectiveness

Backed by Dual FDA Breakthrough Designations for
Heart Failure and End Stage Kidney Disease
>1000ml
Volume of fluid removed
per 4 Hr treatment
>40%
Reduction in
NT-ProBNP Levels
>50%
Reduction in diuretics
dosages
0%
Device or procedure
related adverse events
78%
Reduction in Intra Dialytic
Weight Gain (IDWG)
900-1200ml
Volume of fluids removed
per 4.5 Hr treatment
40%
Reduction in
ultrafiltration rates
0%
Device or procedure
related adverse events
Aronson et al. J. Card Fail 2025
Armaly et al. Renal Failure 2024

Leadership

Noam Josephy, MD MBA

Chief Executive Office

Yaacov Nitzan

Chief Technology Officer

Rotem Katzenellenbogen

Chief Product Officer

Stacey Bunk

Vice President, Market Access

Yael Lev Haber

Head of Corporate Affairs

Scientific Advisory Board

William Abraham, MD

Advanced Heart Failure and Transplant Cardiology
Ohio State University

Dan Bensimhon, MD

Director, Advanced Heart Failure & Mechanical Circulatory Support,
Cone Health, Greensboro, NC

Doron Aronson, MD

Director, Inpatient Cardiology Unit,
Rambam MC, Israel

Ron Wald, MD

Director of Hemodialysis,
St. Michael’s Hospital, Toronto Canada

Jennifer E. Flythe, MD

Chief, UNC Division of Nephrology & Hypertension
UNC School of Medicine

Yoel Fink, PhD

Danae & Vasilis Salapatas
Professor in Materials Science & Engineering,
Massachusetts Institute of Technology